NIH Obesity Research Task Force Symposium: Clinical Research Strategies for Sustainable Obesity Care
- This event has passed.
December 3, 2025
Highly effective anti-obesity medications (AOMs), including semaglutide and tirzepatide, can produce mean weight loss of greater than 15% and have shown effectiveness in the prevention or control of obesity-related comorbidities and complications, such as type 2 diabetes, major cardiovascular events, obstructive sleep apnea, osteoarthritis, chronic kidney disease, heart failure with preserved ejection fraction, and metabolic dysfunction-associated steatohepatitis. Although evidence from industry-sponsored clinical trials shows average regain of two-thirds of initial weight loss after discontinuation of highly effective AOMs, the magnitude of weight regain in individuals is variable and the predictors of this variability are unknown.
This symposium will explore clinical research strategies for generating evidence to guide individualized decisions for long-term maintenance of health gains after initial obesity treatment success with highly effective AOMs.